RARE-51. RITUXIMAB, METHOTREXATE, BCNU, ETOPOSIDE, AND PREDNISONE (RMBVP) FOR THE TREATMENT OF RELAPSED/RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE SINGLE CE...

Por Reiss, Samantha, Yerram, Prakirthi, Modelevsky, Lisa, Grommes, Christian
Publicado no Neuro Oncol (2019)

Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas

Por Reiss, Samantha N., Yerram, Prakirthi, Modelevsky, Lisa, Grommes, Christian
Publicado no J Immunother Cancer (2017)

ACTR-94. TOXICITY OF SINGLE AGENT CARMUSTINE VERSUS CARMUSTINE PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT OR PROGRESSIVE HIGH GRADE GLIOMAS

Por Yerram, Prakirthi, Reiss, Samantha, Modelevsky, Lisa, Gavrilovic, Igor, Kaley, Thomas
Publicado no Neuro Oncol (2017)

Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas

Por Yerram, Prakirthi, Reiss, Samantha N, Modelevsky, Lisa, Gavrilovic, Igor T, Kaley, Thomas
Publicado no J Neurooncol (2019)

Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma

Por Modelevsky, Lisa, Tizon, Richard, Reiss, Samantha N, Smith, Marcel, Garonce, Rachel, Kaley, Thomas
Publicado no CNS Oncol (2018)